<DOC>
	<DOCNO>NCT00678054</DOCNO>
	<brief_summary>This Phase II study test efficacy exogenously administer GM-CSF prostate cancer patient fail definitive local therapy , serologic ( PSA ) evidence progression .</brief_summary>
	<brief_title>Study Granulocyte-Macrophage Colony-Stimulating Factor ( GM-CSF ) Patients With Rising Prostate-Specific Antigen ( PSA )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologic diagnosis adenocarcinoma prostate ; stage T1T3 , N0N1 , M0 Prior definitive therapy primary prostate cancer consist : external beam radiotherapy ; brachytherapy without pelvic external beam radiation ; radical prostatectomy without adjuvant salvage radiation therapy Therapeutic PSA response primary therapy 1.0 ng/ml post radiation therapy 0.4 ng/ml radical prostatectomy Patients treat adjuvant salvage radiation therapy follow radical prostatectomy eligible provide : Post prostatectomy PSA never &gt; 6.0 ng/ml , last effective day androgen deprivation least 3 month prior study entry Recurrent PSA level elevation ( 0.4 ng/ml 6.0 ng/ml ) two determination least one week apart . No clinical evidence gross local recurrence know metastatic disease PSA elevation . Transrectal ultrasound and/or biopsy evaluate local recurrence require . All patient receive bone scan CT scan abdomen exclude metastasis . Estimated life expectancy least 6 month . ECOG Performance status 0 1 . Willing able give inform consent . Cryosurgery definitive therapy primary tumor . Any metastasis . No concurrent prior malignancy allow except follow : adequately treat basal squamous cell skin cancer , adequately treated Stage I II cancer patient currently complete remission , cancer patient diseasefree 5 year . Current systemic steroid therapy ( inhaled topical steroid acceptable ) . Prior hormonal therapy treatment progressive disease . Prior chemotherapy , immunotherapy , therapy experimental agent prostate cancer . Any surgery within prior 4 week . Bilirubin SGOT &gt; 2 x upper limit normal . BUN serum creatinine &gt; 2.0 time normal . No active congestive heart failure . If history clinically significant obstructive airway disease , DLCO must exceed 50 % . Active uncontrolled bacterial , viral fungal infection condition correct control . Any underlying medical condition principal investigator 's opinion make administration GMCSF hazardous obscure interpretation adverse event . PSA &gt; 6.0 ng/ml</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>